In Section A, contributors will get unique doses and schedules of oral ABBV-744 pill to recognize Harmless dosing regimen. Added contributors will probably be enrolled in the recognized monotherapy dosign routine. In Section B, members will acquire oral ruxolitinib and ABBV-744 will probably be supplied as "increase-on" therapy. In Segment https://clinicaltrialrecruitmentf57902.is-blog.com/38467043/details-fiction-and-clinical-trial-recruitment-for-abbv-744-study